Pediatric use of omalizumab for allergic asthma.

Giovanni Battista Pajno Riccardo Castagnoli Stefania Arasi Gian Luigi MarsegliaLucia CaminitiGian Luigi Marseglia

Published in: Expert opinion on biological therapy (2020)

The clinical efficacy and safety of omalizumab for the treatment of pediatric asthma is well documented in clinical trials and observational studies. Further studies are still required to characterize the potential benefit of anti-IgE therapy in airway remodeling, identify additional biomarkers of clinical response and address current unmet needs, including the limit on omalizumab use in children younger than six years.

Keyphrases

clinical trial
chronic obstructive pulmonary disease
allergic rhinitis
lung function
young adults
randomized controlled trial
risk assessment
cystic fibrosis
bone marrow
open label
mesenchymal stem cells
case control
childhood cancer
replacement therapy
phase iii